pomalidomide has been researched along with plx4032 in 1 studies
Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) | Studies (plx4032) | Trials (plx4032) | Recent Studies (post-2010) (plx4032) |
---|---|---|---|---|---|
623 | 121 | 552 | 1,657 | 103 | 1,587 |
Protein | Taxonomy | pomalidomide (IC50) | plx4032 (IC50) |
---|---|---|---|
Chain A, AKAP9-BRAF fusion protein | Homo sapiens (human) | 0.031 | |
RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 0.182 | |
Serine/threonine-protein kinase A-Raf | Homo sapiens (human) | 0.521 | |
Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.0897 | |
Serine/threonine-protein kinase B-raf | Mus musculus (house mouse) | 0.03 | |
Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.36 | |
Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | 1.5 | |
Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 1.5 | |
Mitogen-activated protein kinase kinase kinase 20 | Homo sapiens (human) | 0.0272 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abudayyeh, A; Doshi, M; Edeani, A; Glezerman, IG; Jhaveri, KD; Monga, D; Rosner, M; Wanchoo, R | 1 |
1 review(s) available for pomalidomide and plx4032
Article | Year |
---|---|
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Everolimus; Humans; Imidazoles; Immunologic Factors; Indoles; Kidney Diseases; Lenalidomide; Multiple Myeloma; Nivolumab; Oligopeptides; Oximes; Proteasome Inhibitors; Protein Kinase Inhibitors; Sulfonamides; Thalidomide; Vemurafenib | 2017 |